moxifloxacin has been researched along with montelukast in 7 studies
Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (montelukast) | Trials (montelukast) | Recent Studies (post-2010) (montelukast) |
---|---|---|---|---|---|
3,157 | 552 | 1,690 | 1,965 | 598 | 777 |
Protein | Taxonomy | moxifloxacin (IC50) | montelukast (IC50) |
---|---|---|---|
Epidermal growth factor receptor | Homo sapiens (human) | 3.197 | |
Tyrosine-protein kinase Fyn | Homo sapiens (human) | 4.702 | |
Beta-2 adrenergic receptor | Homo sapiens (human) | 3.488 | |
Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 2.689 | |
Alpha-2A adrenergic receptor | Homo sapiens (human) | 3.919 | |
Adenosine receptor A3 | Homo sapiens (human) | 0.434 | |
Cytochrome P450 2C8 | Homo sapiens (human) | 0.7 | |
Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 8.045 | |
Beta-3 adrenergic receptor | Homo sapiens (human) | 4.3 | |
Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.434 | |
Alpha-2C adrenergic receptor | Homo sapiens (human) | 5.279 | |
Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 6.626 | |
Substance-K receptor | Homo sapiens (human) | 3.822 | |
Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 2.689 | |
Thromboxane-A synthase | Homo sapiens (human) | 1.525 | |
D(3) dopamine receptor | Homo sapiens (human) | 7.747 | |
Delta-type opioid receptor | Homo sapiens (human) | 4.795 | |
5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 6.256 | |
Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.434 | |
Sodium-dependent dopamine transporter | Homo sapiens (human) | 2.601 | |
Mitogen-activated protein kinase 14 | Homo sapiens (human) | 0.856 | |
Leukotriene C4 synthase | Homo sapiens (human) | 5 | |
Cysteinyl leukotriene receptor 1 | Homo sapiens (human) | 0.0015 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (42.86) | 29.6817 |
2010's | 4 (57.14) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Bellon, H; Heigl, T; Hoet, P; Lammertyn, E; Mathyssen, C; Pilette, C; Sacreas, A; Vanaudenaerde, BM; Vandermeulen, E; Verleden, GM; Verleden, SE; Vos, R; Vriens, H | 1 |
1 review(s) available for moxifloxacin and montelukast
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
6 other study(ies) available for moxifloxacin and montelukast
Article | Year |
---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Interleukin-1α induced release of interleukin-8 by human bronchial epithelial cells in vitro: assessing mechanisms and possible treatment options.
Topics: Acetates; Acetylcysteine; Aminopyridines; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Azithromycin; Benzamides; Bronchi; Cell Line; Cyclopropanes; Dapsone; Dexamethasone; Dose-Response Relationship, Drug; Epithelial Cells; Fluoroquinolones; Humans; Interleukin-1alpha; Interleukin-8; MAP Kinase Signaling System; Moxifloxacin; Neutrophils; Phosphorylation; Pyridones; Quinolines; Sulfides; Theophylline; Treatment Outcome | 2017 |